These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39362190)

  • 1. Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients.
    Yao W; Diao R; Yang B; Wang Y; Li B; Li T; Ge L; Yu Y; Zhu R; Wang H
    Int Arch Allergy Immunol; 2024 Oct; ():1-11. PubMed ID: 39362190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
    Hioki C; Oda Y; Moriwaki S; Fukunaga A
    J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
    Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.
    Buttgereit T; Vera Ayala C; Aykanat S; Weller K; Gutsche A; Maurer M; Magerl M
    Front Immunol; 2024; 15():1405317. PubMed ID: 38799421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.
    Wong JCY; Chiang V; Lam DLY; Lee E; Lam K; Au EYL; Li PH
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100166. PubMed ID: 38024849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report.
    Gidaro A; La Cava L; Donadoni M; Popescu Janu V; Cogliati C; Brucato AL; Zanichelli A; Cancian M; Bizzi E
    Front Immunol; 2024; 15():1472390. PubMed ID: 39399485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
    Hide M; Ohsawa I; Nurse C; Yu M;
    J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis.
    Anderson J; Soteres D; Tachdjian R; Mellor J; Earl L; Connolly H; Wynne-Cattanach K; Moran K; Sing K; Schultz BG; Juethner S
    Allergy Asthma Proc; 2024 Nov; 45(6):426-433. PubMed ID: 39293940
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.
    Iaboni A; Kanani A; Lacuesta G; Song C; Kan M; Betschel SD
    Allergy Asthma Clin Immunol; 2021 Jul; 17(1):78. PubMed ID: 34301329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema.
    Itzler R; Lumry WR; Sears J; Braverman J; Li Y; Brennan CJ; Koch GG
    Orphanet J Rare Dis; 2024 Jun; 19(1):241. PubMed ID: 38909246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.
    Magerl M; Schiffhorst G; Fanter L; Müller G; Hirche C; Berkemeier F; Aygören E
    Allergy; 2024 Jan; 79(1):215-224. PubMed ID: 37641968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.
    Craig T; Tachdjian R; Bernstein JA; Anderson J; Nurse C; Watt M; Yu M; Juethner S
    Ann Allergy Asthma Immunol; 2024 Dec; 133(6):712-719.e1. PubMed ID: 39128590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
    Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
    Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
    Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.
    Anderson J; Maina N
    Clin Transl Allergy; 2022 Jan; 12(1):e12092. PubMed ID: 35079346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.
    Lumry WR; Weller K; Magerl M; Banerji A; Longhurst HJ; Riedl MA; Lewis HB; Lu P; Devercelli G; Jain G; Maurer M;
    Allergy; 2021 Apr; 76(4):1188-1198. PubMed ID: 33258114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
    Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J
    J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.